Metformin Ennogen Ip

Metformin, the active ingredient in Metformin Ennogen Ip, is a Biguanide presented as an oral formulation for Oral use. It treats type 2 diabetes mellitus in adults by improving blood‑sugar control.

GNH USA supplies Metformin Ennogen Ip as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin is used in the management of disorders related to glucose metabolism and insulin resistance.

Type 2 diabetes mellitus: lowers fasting plasma glucose and HbA1c to improve glycemic control. Gestational diabetes mellitus: may be prescribed when diet alone is insufficient, under medical supervision. Polycystic ovary syndrome: can improve insulin sensitivity and help regulate menstrual cycles when indicated by a clinician.

Metformin may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: transient stomach upset that often resolves with continued use. - Diarrhea: loose stools, usually mild to moderate. - Abdominal discomfort: cramping or pain in the stomach area. - Metallic taste: a transient metallic sensation in the mouth. - Loss of appetite: reduced desire to eat. - Flatulence: increased gas production.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening buildup of lactic acid. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: abnormal liver enzyme elevations. - Hypoglycemia: especially when combined with other glucose‑lowering agents. - Vitamin B12 deficiency: may develop with long‑term therapy. - Acute pancreatitis: inflammation of the pancreas.

Metformin requires careful consideration of patient‑specific factors before initiation.

Renal function assessment: avoid use in severe renal impairment (eGFR <30 mL/min/1.73 m²). Liver disease monitoring: contraindicated in acute or chronic hepatic failure. Risk of lactic acidosis: discontinue before any radiographic contrast studies. Vitamin B12 monitoring: periodic testing recommended for long‑term therapy. Alcohol consumption: limit intake to reduce lactic acidosis risk. Store at ambient temperature: keep in the original pack, protect from moisture and heat.

Metformin can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate lactic acidosis; hold metformin before and after use. - Cimetidine: can increase metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis. - Diuretics (loop or thiazide): may impair renal function, raising metformin levels. - Nifedipine: may increase metformin exposure.

Moderate Interactions (Monitor Closely): - Sulfonylureas: combined therapy raises hypoglycemia risk. - Beta‑blockers: may mask hypoglycemia symptoms. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Warfarin: may affect INR stability. - Digoxin: watch for altered serum concentrations.